Alex Nivorozhkin News Today

- Publication explores structure-activity relationships of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2...

TORONTO, November 15, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience ("SFN") taking place November 11-15, 2022, in Washington, D.C.

TORONTO - Cybin Inc. , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today...

- Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” - - Highlights preclinical work done to support...

15.11.2022 - Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that the Company presented a poster highlighting preclinical data for its deuterated ... Seite 1

 Cybin Inc. Releases Financial Highlights and Provides Business Update Successful bought deal offering brings total capital raised to-date to approximately $90 million — — Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines – — Adelia Therapeutics acquisition expands scientific team, IP portfolio and diversifies development pipeline — — Partnership with Kernel provides access to neuroimaging … — Succ...

Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “ Transaction”). Transaction Highlights Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments. Adelia brings a range of technolo...

), which this week acquired Adelia Therapeutics, a transformational move that broadened addressable indications in its pipeline and strengthened its scientific team. Cybin has a three-pillar approach,  its initial sights set on treating major depression disorder (MDD) now expanded to address additional indication as well through innovative psychedelic therapeutics development and unique delivery technologies. Cybin stands shoulder-to-shoulder with peers striving for a world of better mental we...

Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “ Transaction”). Transaction Highlights Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments. Adelia brings a range of technolo...